Compare Heron Therapeutics Inc (HRTX) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Heron Therapeutics Inc trades at $0.38 (market cap $68.01M), while Global X NASDAQ 100 Covered Call ETF trades at $18.68 (market cap $8.49B). The key difference: Global X NASDAQ 100 Covered Call ETF is far larger — about 124.8× Heron Therapeutics Inc's market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Global X NASDAQ 100 Covered Call ETF for 50 Days on average.
| HRTX | QYLD | |
|---|---|---|
Market Cap | $68.01M | $8.49B |
Volume | 1,891,941 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.49 | $18.68 |
52-Week Low | $0.27 | $16.70 |
Typical Hold Time | 35 Days | 50 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
QYLD trades at $18.675, down slightly by 0.03% on the day. The ETF shows a bullish technical signal from moving averages but bearish oscillators, with RSI levels indicating potential overbought conditions. Recent dividend payments of $0.18 per share were distributed monthly, supporting its income-focused strategy. News coverage highlights its high yield but also raises concerns about long-term capital erosion and capped upside.
The outlook for QYLD is mixed; it offers attractive monthly income but faces headwinds from declining option premiums and limited growth potential. Risks include principal erosion and tax implications, making it suitable for income-seeking investors who prioritize cash flow over capital appreciation. Analyst sentiment varies, with some upgrades citing yield attractiveness amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
